Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
Autoimmune Disease, Mental Disorder, Obsessive Compulsive Disorder
About this trial
This is an interventional treatment trial for Autoimmune Disease focused on measuring Amoxicillin, Antibiotics, Cytokines, Group A beta-Hemolytic Strep Infections, Obsessive Compulsive Disorder, Streptococcal Infection, Tic Disorders
Eligibility Criteria
Subjects with presence of OCD and/or tic disorder: Must meet lifetime diagnostic criteria (DSM III or DSM IV) for obsessive compulsive disorder or a tic disorder. Pediatric onset: Symptoms of the disorder first become evident between 3 years of age and the beginning of puberty, as is generally true for rheumatic fever. Episodic course of symptom severity: Clinical course is characterized by the abrupt onset of symptoms or by dramatic symptom exacerbations. Episodic course is characterized by waxing and waning or symptom severity with greater than +20 percent fluctuation from baseline. Association with GABHS infection: Symptom onset or exacerbations must be temporally related to group A B-Hemolytic Streptococcal infections (GABHS), i.e., associated with positive throat culture and/or elevated anti-GABHS antibody titers. Association with neurological abnormalities: During symptom exacerbations, patients will have an abnormal neurological examination, such as motoric hyperactivity and adventitious movements (i.e., choreiform movements or tics). Subjects must report history of improvement in their tics and/or OCD when treated with amoxicillin. No subjects who meet criteria for Autism. No subjects who have neurologic disorders other than tics/TS. No subjects who have and IQ less than 80. No subjects who have a serious concurrent or chronic medical illness. No subjects who have a history of penicillin or amoxicillin allergy. No subjects with history of noncompliance with medical procedures.
Sites / Locations
- National Institute of Mental Health (NIMH)